Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Xamoterol in sinus node disease

P G Avery1, J Small, D B Shaw

  • 1Department of Cardiology, Royal Devon and Exeter Hospital, Wonford, UK.

International Journal of Cardiology
|June 15, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heterogeneous mass distribution of the rubble-pile asteroid (101955) Bennu.

Science advances·2020
Same author

The dynamic geophysical environment of (101955) Bennu based on OSIRIS-REx measurements.

Nature astronomy·2020
Same author

A Portable, Discrete-Sampling Submersible Plankton Pump and Its Use in Sampling Starfish Eggs.

The Biological bulletin·2017
Same author

Keratinocyte Carcinoma as a Marker of a High Cancer-Risk Phenotype.

Advances in cancer research·2016
Same author

Numerical evolution.

Acta biotheoretica·2014
Same author

Primary idiopathic segmental infarction of the greater omentum.

Canadian Medical Association journal·2010
Same journal

Severe tricuspid regurgitation is a congestion-driven cardiorenal disease: A longitudinal study defining a right heart failure phenotype.

International journal of cardiology·2026
Same journal

Applicability of ischemic heart disease clinical practice guidelines in low- and middle-income countries.

International journal of cardiology·2026
Same journal

Effectiveness of a new diagnostic algorithm for the diagnosis of unexplained syncope in patients with hypertrophic cardiomyopathy.

International journal of cardiology·2026
Same journal

The predictive role of the FIB-4 index in identifying arrhythmic risk among patients with nonischemic dilated cardiomyopathy.

International journal of cardiology·2026
Same journal

Beyond arrhythmias: Exploring heart failure in arrhythmogenic cardiomyopathy.

International journal of cardiology·2026
Same journal

Corrigendum to "First-in-human study of the K-Clip™ transcatheter annular repair system for severe functional tricuspid regurgitation" [International Journal of Cardiology 390(2023) / IJCA 131174].

International journal of cardiology·2026
See all related articles

Xamoterol, a beta-receptor partial agonist, increased heart rate and reduced pauses in some patients with sinoatrial disorder. This offers a potential pharmacological alternative to pacemaker implantation for certain individuals.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Pacemaker implantation for sinoatrial disorder has limitations.
  • A pharmacological alternative could benefit specific patient groups.

Purpose of the Study:

  • To evaluate Xamoterol's efficacy in patients with sinoatrial disease.
  • To assess heart rate and sinus pauses using Holter monitoring.

Main Methods:

  • Double-blind, cross-over trial involving 10 patients.
  • Comparison of Holter monitoring data during Xamoterol treatment versus placebo.
  • Analysis of mean heart rates and sinus pause characteristics.

Main Results:

  • Xamoterol significantly increased mean heart rates during early morning hours (1:00-9:00).

Related Experiment Videos

  • Sinus pauses were reduced or eliminated in six patients.
  • Three patients experienced an increased frequency of sinus pauses.

    • Conclusions:

    • Xamoterol can increase heart rate and decrease sinus pauses in some patients with sinoatrial disorder.
    • The drug's effectiveness varies among individuals, suggesting personalized treatment approaches.
    • Xamoterol presents a potential, albeit not universally effective, pharmacological option for managing sinoatrial disease.